Breaking News Instant updates and real-time market news.

2017-07-24 09:04:56

JAGX

Jaguar Health

$0.71

0.02 (2.90%)

09:04

07/24/17

07/24

09:04

07/24/17

09:04

Napo Pharmaceuticals, Jaguar Animal Health announce crofelemer data

Napo Pharmaceuticals and Jaguar Animal Health announced the results of a supplemental analysis of the long-term trial of crofelemer in patients with chronic HIV-related diarrhea. The analysis revealed a mean decrease of over 70% in diarrhea episodes versus baseline and over 50% of patients with complete resolution of their diarrhea. The results were reported at the 9th International AIDS Society Conference on HIV Science on Wednesday, July 26 in Paris, France. Mytesi is the only drug that has been specifically studied in and FDA-approved for use in managing diarrhea in people living with HIV. The safety and efficacy of crofelemer in reducing HIV-related diarrhea were assessed in the ADVENT trial. While the primary efficacy and safety results have previously been reported, this supplemental analysis was conducted to provide a more complete understanding of the long-term efficacy of crofelemer in patients with chronic HIV-related diarrhea. Prior to study entry, patients enrolled in the ADVENT trial had an average of 20 watery stools per week. Key results of this analysis showed: An average reduction of 73% in diarrhea episodes by week 24 of crofelemer treatment; More than 75% of patients had a clinically meaningful reduction in diarrhea, as measured by at least a 50% decrease in the number of episodes; More than 50% of patients had a complete resolution of their diarrhea by week 24 of crofelemer treatment; There was no significant difference between patients who were taking a protease inhibitor and those who were not or based upon the cause of the diarrhea.

JAGXJaguar Health

$0.71

0.02 (2.90%)

07/11/17

RODM

07/11/17INITIATIONTarget $2RODMBuy

Jaguar Animal Health initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw analyst Raghuram Selvaraju started Jaguar Animal Health with a Buy rating and $2 price target. The company currently trades at a valuation below $10M, despite the regulatory approval for Mytesi and the market presence of Neonorm, the analyst writes.

Snap Inc. (SNAP) is banning ads of initial coin offerings in its Snapchat app, Cheddar reports, citing a company spokesperson. The decision makes Snapchat the latest social media platform to prohibit advertisements for cryptocurrency ICOs, the report says. In contrast to Facebook (FB) and Google (GOOG), however, Snap's current block of ICOs has been in effect since early February and does not apply to different kinds of cryptocurrency ads, the report says. Reference Link

Airbus (EADSY) is mulling making a freighter version of its slow-selling A330neo widebody, spurred by requests from potential customers Amazon (AMZN) and UPS (UPS), Bloomberg reports, citing people familiar with the matter. The interest from Amazon and UPS could incite a competition between Airbus and rival Boeing (BA) as the worldwide air-cargo market rebounds from a slump, the report notes.

Facebook's chief information security officer, Alex Stamos, will leave the company after internal disagreements over how the social network should deal with its role in spreading disinformation, The New York Times reports, citing current and former employees briefed on the matter. Reference Link

Amazon has considered the possibility of expanding its retail footprint by acquiring some stores from bankrupt Toys 'R' Us, Bloomberg reports, citing people with knowledge of the situation. The e-commerce giant is not interested in maintaining the Toys 'R' Us brand, but has mulled using the soon-to-be-vacant stores for its own purposes, the report says. Reference Link

President Trump is readying to place a package of $60B in annual tariffs against China, following through on a long-time threat that he claims will punish China for IP infringement and create more jobs in the U.S., the Washington Post reports. The tariff package, which the president intends to unveil by the end of the week, was confirmed by four senior administration officials, the report notes. Senior aides has presented Trump with a $30B tariff package that would apply to a variety of products, but the president directed them to approximately double the amount of new trade levies, the report says. The package could be applied to over 100 products, which the president contends were made by using trade secrets that the Chinese stole from U.S. companies or forced them to hand over in exchange for market aces, the report says. Reference Link